Sanofi Extends, Revamps Discovery Pact With Warp Drive
This article was originally published in Scrip
Sanofi SA has extended and revamped its existing discovery pact with Warp Drive Bio - a move that increases chances the French group will buy the Boston-based biotech if they successfully use its two computational platforms to find new oncology drugs and antibiotics based on natural products.
You may also be interested in...
Once expected to be absorbed by Sanofi, US biotech Warp Drive Bio now will become part of California’s Revolution Medicines in a stock transaction. Sosei elects against its option to acquire MiNA Therapeutics; MeiraGTX follows its June IPO with takeout of Vector Neurosciences. Other recent mergers and acquisitions...
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.